Search
Contusugene ladenovec
go.drugbank.com/drugs/DB05322InvestigationalINGN 201(Advexin) is a replication-impaired adenoviral vector that carries the p53 gene, has been evaluated in both preclinical and clinical trials. … Advexin is a well-tolerated and efficacious treatment for numerous cancers, both as monotherapy and in combination with radiation and/or chemotherapy agents.
Categories: Complex MixturesDetomidine
go.drugbank.com/drugs/DB11556InvestigationalVet approvedCurrently, it is only approved by the FDA for use in horses but has been studied for use in other large animals. … Detomidine is an α2-adrenergic agonist that is used as a horse sedative. Normally, it is administered in the salt form, detomidine hydrochloride.
Influenza B virus B/Austria/1359417/2021 live (attenuated) antigen
go.drugbank.com/drugs/DB16902ApprovedInactivated viruses cannot replicate and thus cannot cause disease from infection, even in immunocompromised individuals. … These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen
Influenza A virus A/Darwin/6/2021 IVR-227 (H3N2) antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB16903ApprovedWithdrawnInactivated viruses cannot replicate and thus cannot cause disease from infection, even in immunocompromised individuals. … These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen
Influenza B virus B/Singapore/WUH4618/2021 antigen (MDCK cell derived, propiolactone inactivated)
go.drugbank.com/drugs/DB16910ApprovedInactivated viruses cannot replicate and thus cannot cause disease from infection, even in immunocompromised individuals. … These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen
Influenza A virus A/Darwin/11/2021 (H3N2) antigen (MDCK cell derived, propiolactone inactivated)
go.drugbank.com/drugs/DB16914ApprovedWithdrawnInactivated viruses cannot replicate and thus cannot cause disease from infection, even in immunocompromised individuals. … These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen
Influenza A virus A/Delaware/55/2019 CVR-45 (H1N1) antigen (MDCK cell derived, propiolactone inactivated)
go.drugbank.com/drugs/DB16915ApprovedWithdrawnInactivated viruses cannot replicate and thus cannot cause disease from infection, even in immunocompromised individuals. … These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen
Influenza B virus B/Austria/1359417/2021 BVR-26 antigen (propiolactone inactivated)
go.drugbank.com/drugs/DB16919ApprovedWithdrawnInactivated viruses cannot replicate and thus cannot cause disease from infection, even in immunocompromised individuals. … These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen
Omega-6 fatty acids
go.drugbank.com/drugs/DB13168InvestigationalNutraceuticalCells involved in the inflammatory response are typically rich in the n-6 fatty acid arachidonic acid, as generally, eicosanoids derived from n-6 PUFA are pro-inflammatory. … Omega-6 fatty acids are polyunsaturated fatty acids with a final carbon-carbon double bond in the n-6 position, that is, the sixth bond, counting from the methyl end.
Synonyms: n-6 fatty acidsBG-777
go.drugbank.com/drugs/DB05839ExperimentalBG-777 is an immunomodulator with proven efficacy against viral and bacterial infections in preclinical studies.